Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time
Caladrius Biosciences, Inc. (Nasdaq: CLBS) will report its financial results for Q2 2022 on August 4, 2022, at 4:30 p.m. EDT. The call will feature a new conference registration process, with participants advised to register in advance. Caladrius focuses on developing innovative therapies, including XOWNA® (CLBS16) for coronary microvascular dysfunction and CLBS12 (HONEDRA®) for critical limb ischemia. The company recently entered a merger agreement with Cend Therapeutics to form Lisata Therapeutics, anticipated to close in Q3 2022, enhancing its development pipeline.
- Merger agreement with Cend Therapeutics expected to enhance pipeline and financial strength.
- Ongoing clinical trials for promising therapies, particularly XOWNA® and CLBS12.
- None.
BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that the Company will report its financial results for the three and six months ended June 30, 2022, on Thursday, August 4, 2022, at 4:30 p.m. (EDT).
The Company is utilizing a new conference call service. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.
A live webcast of the call will also be accessible under the Investors & News section of the Caladrius website and will be available for replay beginning two hours after the conclusion of the call for 12 months.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease. We currently are developing first-in-class autologous cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company’s current product candidates include: XOWNA® (CLBS16), the subject of both a recently completed positive Phase 2a study and an ongoing Phase 2b study (www.freedom-trial.com) in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS12 (HONEDRA® in Japan), recipient of a SAKIGAKE designation in Japan and eligible for early conditional approval for the treatment of critical limb ischemia (“CLI”) and Buerger’s disease based on the results of an ongoing clinical trial; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease (“DKD”). For more information on the Company, please visit www.caladrius.com.
The Company recently announced that it has signed a definitive merger agreement with Cend Therapeutics, Inc. (www.cendrx.com) to form Lisata Therapeutics. Upon closing, Lisata will be a publicly traded company with an advanced clinical development pipeline and strong balance sheet, which is expected to fund product candidates to their next development milestone. The merger is expected to close in the third quarter of 2022.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@caladrius.com
FAQ
When will Caladrius report its financial results for Q2 2022?
What is the significance of the merger between Caladrius and Cend Therapeutics?
What are the main products under development by Caladrius?
How can investors participate in Caladrius' upcoming conference call?
